Simplifying your blood sample analysis with Cell-Free DNA BCT
14 Nov 2023
In this video, Streck provides information on how Cell-Free DNA BCT® can eliminate pre-analytical variation, removing the requirement for immediate plasma isolation. The technology stabilizes cell-free DNA for up to seven days at 6°C to 37°C, featuring a preservative reagent to minimize the release of contaminating cellular genomic DNA during sample handling, shipping, and processing. The stored plasma, including cell-free DNA (cfDNA), remains suitable for use in next-generation sequencing assays cleared or approved for samples collected into Cell-Free DNA BCT.
About the company
Streck
Streck manufactures hematology, chemistry, and immunology products for the clinical laboratory.
Recognized worldwide as the leader in cell stabilization, Streck focuses on the development of quality control and diagnostic products to help meet the fast-paced needs of clinical laboratories, with a continued commitment to innovation.
Related products
Request Quote for All Products
Cell-Free DNA BCT®
StreckFor In Vitro Diagnostic Use. Cell-Free DNA BCT is a direct-draw venous whole blood collection device intended for the collection, stabilization and transport of venous whole blood samples for use in conjunction with cell-free DNA next generation sequencing assays For that have been cleared or approved for use with samples collected into the Cell-Free DNA BCT device. Performance characteristics of this device have only been established on the Guardant360 CDx assay.
